Cincinnati/ Science, Tech & Medicine

Cincinnati Hospital Performs First US Robotic Mitral Valve Swap, Patient Sent Home

AI Assisted Icon
Published on November 22, 2026
Cincinnati Hospital Performs First US Robotic Mitral Valve Swap, Patient Sent HomeChrist Hospital — First U.S. Robotic Valve Swap Site
Google Street View

Surgeons at The Christ Hospital in Cincinnati completed the first robotic mitral valve replacement procedure performed in the United States on Nov. 9, using an experimental system that lets doctors steer a catheter and position a replacement valve with a handheld controller. The patient went home in stable condition, according to the physician who led the case.

Capstan Medical, the company that built the investigational robot, announced the milestone last Monday, saying the procedure was carried out at The Christ Hospital in Cincinnati as part of an FDA-authorized early feasibility study. The company said the case was led by Dr. Santiago Garcia, who directs The Christ Hospital's structural heart program, and that the patient was discharged home in stable condition. As WKRC reported, Garcia said the robotic platform is designed for catheter stability and control, aiming to allow more precise placement of the valve implant.

The system, known as the Capstan Compass, combines a flexible, multi-axis catheter, robotic navigation and a novel valve implant, with physicians directing catheter movement, valve positioning and deployment through a handheld controller, per the company's announcement. It remains investigational and is not approved for commercial use in the United States. No details about the patient's identity, diagnosis or broader medical history were disclosed in the announcement.

Why the Mitral Valve Is Such a Tough Target

The mitral valve helps control blood flow through the heart, and when it fails to close properly, blood can flow backward — a condition known as mitral regurgitation. Some patients with mitral valve disease are considered too high-risk for conventional open-heart surgery, and existing catheter-based treatments aren't suitable for everyone, which is part of why Capstan Medical is developing this robotic approach as a minimally invasive option for structural heart disease.

Getting a device into the mitral valve safely has proven far harder than doing the same for the aortic valve. The station's report on the anatomy behind the challenge aligns with broader industry coverage: according to MedTech Dive, transcatheter mitral valve replacement has developed more slowly than its aortic counterpart specifically because of the mitral valve's complex anatomy. The outlet has also reported, citing Capstan executive Maggie Nixon, that more than 80% of patients who seek mitral replacement with devices currently under investigation are excluded because of anatomical constraints.

A Second Milestone After Chile

This wasn't Capstan's first time testing the device in a human patient. The company's investigational robot was previously used in two patients at Hospital Clínico Universidad Católica in Santiago, Chile, with procedures completed and announced in March 2025. Garcia supported those cases alongside Dr. Gonzalo Martinez, and Capstan said both Chilean patients had their mitral regurgitation eliminated, with unobstructed blood flow from the heart's left ventricle, and were released home after a few days.

The National Heart, Lung, and Blood Institute has described mitral valve replacement and repair broadly as high-risk procedures that aren't suitable for many patients, underscoring the stakes behind efforts like Capstan's to find less invasive alternatives. Any device moving through an FDA-authorized early feasibility study is still a long way from a market-ready product, and federal rules reflect that distinction: the U.S. Food and Drug Administration notes that an approved Investigational Device Exemption simply permits a device to be shipped for study purposes without meeting the full set of requirements that apply once a device reaches commercial distribution.

For now, the Cincinnati procedure stands as a single case within an early-stage trial, with Capstan and The Christ Hospital pointing to it as evidence the robotic approach can work outside of Chile. Whether it eventually reshapes treatment options for Cincinnati-area patients with mitral valve disease will depend on how the broader feasibility study unfolds.